 The drug is available in vials containing 100 mg each.There is little information about the pharmacokinetic properties of gusperimus.The European Commission assigned orphan drug status to Gusperimus in 2001 for the treatment of granulomatosis with polyangiitis, a serious form of vasculitis frequently associated with permanent disability and/or fatal outcome.